Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

NCT06489548 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Dementia
Alzheimers Disease
Mild Cognitive Impairment Due to Alzheimer's Disease

Interventions

DRUG: Foralumab TZLS-401 50 µg
DRUG: Foralumab TZLS-401 100 µg

Sponsor

Brigham and Women's Hospital

Collaborators

[object Object]